RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, will be collaborating with the University of Milan, Italy, on a new wellness line of topical patches. The partnership will be testing the permeation and effectiveness of the patches, which RYAH developed for its Smart Patch system. University scientists are focused on determining the permeation effectiveness of vitamin and nutraceutical patches as an alternative slow-release, nondigested solution to consumer intake; they will also use the RYAH Smart Patch “boost capability” to monitor and calculate the impact that precise, intermittent heat has on the delivery of the patch loadings. According to the announcement, RYAH’s Smart Patch is an IoT-powered device that enables users to monitor and track their patch formulation usage, body location of patch, length of use and personal effectiveness. The Smart Patch also features a prescheduled “boost” capability for specific formulations that may experience increased permeability with a precise, controlled, and gentle heating capability. “We are pleased to be engaging in another meaningful research project with our partners at the University of Milan,” said RYAH Group CEO Gregory Wagner in the press release. “This new project follows an ongoing, ambitious collaboration with the Department of Chemical Analysis led by Professor Gabriella Roda, with the objective to publish a scientific study on the performance of the RYAH Smart Medical inhaler. RYAH remains committed to providing effective delivery solutions combined with powerful data insights across a wide range of medicines, vitamins and nutraceuticals. The development of our wellness line combined with the RYAH Smart Patch system, is a perfect example of our commitment to keep current with important consumer trends in this expanding industry.”
To view the full press release, visit https://ibn.fm/gvuql
About RYAH Group Inc.
RYAH is a connected device, and big data and technology company focused on valuable, captive, anonymized data analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies, as well as licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. For more information about the company, please visit www.RyahGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical…
Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a…
HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a…
Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive…
BioVaxys (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) and SpayVac-for-Wildlife announced an expansion of the fields…